CMS Announces Significant 2027 Reductions on 15 High-Cost Medicare Drugs
CMS sets 2027 maximum fair prices for 15 high-cost Medicare drugs, cutting costs by up to 85% and saving $12 billion annually under Inflation Reduction Act measures.
Novo Nordisk Faces CMS Drug Price Cuts but New Indications Offer Growth Potential
Novo Nordisk's semaglutide drugs face significant Medicare price reductions under CMS negotiation rules starting 2027, but new indications could drive future revenue growth.
Federal Move to Cut Obesity Drug Prices Expands Medicare Coverage
The federal government lowers obesity drug prices and expands Medicare coverage, impacting millions of patients and primary care providers with new access and cost structure.
Medicare Drug Price Negotiations Yield $12 Billion Savings on 15 Key Medications
New Medicare drug price negotiations under the Inflation Reduction Act cut costs for 15 major medications, saving Medicare $12 billion annually.
U.S. Healthcare and Insurance Outlook for 2026: AI, Policy, and Market Trends
Comprehensive 2026 outlook on U.S. healthcare and insurance sector covering AI adoption, Medicare Advantage growth, pharmaceutical scrutiny, market consolidations, and emerging health equity focus.
Medicare Drug Price Negotiations Cut Costs for 15 Key Medications
New Medicare drug price negotiations reduce government costs on 15 high-spend medications, including cancer and diabetes treatments, saving $12 billion annually.
Trump Administration Secures Medicare Drug Price Cuts for 15 Medications
The Trump administration finalizes agreements reducing Medicare prices for 15 drugs, aiming to save billions and impact Medicare Part D plans and drug affordability policies.
Pharma Firms Slash Medicare Drug Prices in Trump Administration Deal
Pharmaceutical companies agree to significant Medicare drug price cuts under Trump administration, projecting billions in savings with impacts on Medicare Part D and drug affordability.
CMS Launches Voluntary Medicaid MFN Drug Pricing Model; Trump-Era Manufacturer Agreements Expand
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
Novo Nordisk, Eli Lilly Cut GLP-1 Prices for Expanded Medicare Market Access
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.